US 12,290,569 B2
Methods and compositions using peptides and proteins with c-terminal elements
Erkki Ruoslahti, La Jolla, CA (US); Tambet Teesalu, La Jolla, CA (US); and Kazuki Sugahara, La Jolla, CA (US)
Assigned to Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US)
Filed by Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US)
Filed on Jul. 12, 2021, as Appl. No. 17/373,496.
Application 17/373,496 is a continuation of application No. 16/524,869, filed on Jul. 29, 2019, granted, now 11,059,718.
Application 16/524,869 is a continuation of application No. 12/821,050, filed on Jun. 22, 2010, granted, now 10,370,245, issued on Aug. 6, 2019.
Claims priority of provisional application 61/249,140, filed on Oct. 6, 2009.
Claims priority of provisional application 61/219,086, filed on Jun. 22, 2009.
Prior Publication US 2022/0175941 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/66 (2017.01); B82Y 5/00 (2011.01)
CPC A61K 47/66 (2017.08) [B82Y 5/00 (2013.01)] 19 Claims
 
1. A composition comprising a CendR element and a co-composition, wherein the CendR element and the co-composition are not covalently coupled and not directly non-covalently associated with each other,
wherein the CendR element comprises the sequence X1X2X3X4, wherein X1 is selected from the group consisting of R, K or H,
wherein X4 is selected from the group consisting of R, K, H, or KG,
wherein X2 and X3 can each be, independently, any amino acid, and
wherein the CendR element does not comprise RRLR (SEQ ID NO:248), RRRR (SEQ ID NO:249), CRCDKPRR (SEQ ID NO:95), or TKPPR (SEQ ID NO:98).